Abstract
In this study the comparative TLC immunostaining investigation of neutral GSLs and gangliosides from human skeletal and heart muscle is described. A panel of specific polyclonal and monoclonal antibodies as well as the GM1-specific choleragenoid were used for the overlay assays, combined with preceding neuraminidase treatment of gangliosides on TLC plates. This approach proved homologies but also quantitative and qualitative differences in the expression of ganglio-, globo- and neolacto-series neutral GSLs and gangliosides in these two types of striated muscle tissue within the same species. The main neutral GSL in skeletal muscle was LacCer, followed by GbOse3Cer, GbOse4Cer, nLcOse4Cer and monohexosylceramide, whereas in heart muscle GbOse3Cer and GbOse4Cer were the predominant neutral GSLs beside small quantities of LacCer, nLcOse4Cer and monohexosylceramide. No ganglio-series neutral GSLs and no Forssman GSL were found in either muscle tissue. GM3(Neu5Ac) was the major ganglioside, comprising almost 70% in skeletal and about 50% in cardiac muscle total gangliosides. GM2 was found in skeletal muscle only, while GD3 and GM1b-type gangliosides (GM1b and GD1α) were undetectable in both tissues. GM1a-core gangliosides (GM1, GD1a, GD1b and GT1b) showed somewhat quantitative differences in each muscle; lactosamine-containing IV3Neu5Ac-nLcOse4Cer was detected in both specimens. Neutral GSLs were identified in TLC runs corresponding to e.g. 0.1 g muscle wet weight (GbOse3Cer, GbOse4Cer), and gangliosides GM3 and GM2 were elucidated in runs which corresponded to 0.2 g muscle tissue. Only 0.02 g and 0.004 g wet weight aliquots were necessary for unequivocal identification of neolacto-type and GM1-core gangliosides, respectively. Muscle is known for the lowest GSL concentration from all vertebrate tissues studied so far. Using the overlay technique, reliable GSL composition could be revealed, even from small muscle probes on a sub-orcinol and sub-resorcinol detection level. Abbreviations: ATCC, American Type Culture Collection; GSL(s), glycosphingolipid(s); HPLC, high performance liquid chromatography; HPTLC, high performance thin layer chromatography; Neu5Ac, N-acetylneuraminic acid; Neu5Gc, N-glycolylneuraminic acid [78]; PBS, phosphate buffered saline. The designation of the following glycosphingolipids follows the IUPAC-IUB recommendations [79] and the ganglioside nomenclature system of Svennerholm [80]. Lactosylceramide or LacCer, Galβ1-4Glcβ1-1Cer; gangliotriaosylceramide or GgOse3Cer, GalNAcβ1-4Galβ1-4Glcβ1-1Cer; gangliotetraosylceramide or GgOse4Cer, Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer; globotriaosylceramide or GbOse3Cer, Galα1-4Galβ1-4Glcβ1-1Cer; globoside or globotetraosylceramide or GbOse4Cer, GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer; Fo or Forssman GSL, GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer; paragloboside or lacto-N-neotetraosylceramide or nLcOse4Cer, Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer; lacto-N-norhexaosylceramide or nLcOse6Cer, Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer; GM3, II3Neu5Ac-LacCer; GM2, II3Neu5Ac-GgOse3Cer; GM1 or GM1a, II3Neu5Ac-GgOse4Cer; GM1b, IV3Neu5Ac-GgOse4Cer; GD3, II3(Neu5Ac)2-LacCer; GD1a, IV3Neu5Ac,II3Neu5Ac-GgOse4Cer; GD1b, (II3Neu5Ac)2-GgOse4Cer; GD1α, IV3Neu5Ac,III6Neu5Ac-GgOse4Cer; GT1b, IV3Neu5Ac,II3(Neu5Ac)2-GgOse4Cer; GQ1b, IV3(Neu5Ac)2, II3(Neu5Ac)2-GgOse4Cer.
Similar content being viewed by others
References
Reuter G, Schauer R (1994) Methods Enzymol 230: 168–99.
Schauer R (1988) Adv Exp Med Biol 228: 47–72.
Hakomori S-I (1981) Annu Rev Biochem 50: 733–64.
Ledeen RW, Yu RK (1982) Methods Enzymol 83: 139–91.
Marcus DM (1984) Mol Immunol 21: 1083–91.
Thompson TE, Tillack TW (1985) Annu Rev Biophys Biophys 14: 361–86.
Fukuda M (1985) Biochim Biophys Acta 780: 119–50.
Stults CLM, Sweeley CC, Macher B (1989) Methods Enzymol 179: 167–214.
Schwarzmann G, Sandhoff K (1990) Biochemistry 29: 10866–71.
Zeller CB, Marchase RB (1992) Am J Physiol 262 (Cell Physiol 31) C1341-C55.
Kojima N, Hakomori S-I (1991) Glycobiology 1: 623–30.
Igarashi Y, Nojiri H, Hanai N, Hakomori S-I (1989) Methods Enzymol 179: 521–41.
Saito M (1989) Dev Growth Differ 31: 509–22.
Hakomori S-I (1990) J Biol Chem 265: 18713–16.
Gillard BK, Thurmon LT, Marcus DM (1993) Glycobiology 3: 57–67.
Nakamura K, Ariga T, Yahagi T, Miyatake T, Suzuki A, Yamakawa T (1983) J Biochem 94: 1359–65.
Mu¬thing J, Maurer U, Šoštarić K, Neumann U, Brandt H, Duvar S, Peter-Katalinić J, Weber-Schu¬rholz S (1994) J Bio-chem 115: 248–56.
Svennerholm L, Bruce Å, Månsson J-E, Rynmark BM, Vanier MT (1972) Biochim Biophys Acta 280: 626–36.
Chien J-L, Hogan EL (1980) In Cell Surface Glycolipids (Sweeley CC, ed) pp. 135–48. NY, American Chemical Society.
Levis GM, Karli JN, Moulopoulos SD (1979) Lipids 14: 9–14.
Čačić M, Müthing J, Krachum I, Neumann U, Weber-Schu¬ r-holz S (1994) Glycoconjugate J 11: 477–85.
Karlsson K-A (1989) Annu Rev Biochem 58: 309–50.
Müthing J (1996) J Chromatogr A 720: 3–25.
Ko¬hler G, Milstein C (1976) Eur J Immunol 6: 511–19.
Feizi T (1985) Nature 314: 53–57.
Magnani J (1987) Chem. Phys. Lipids 42: 65–74.
Müthing J, Peter-Katalinić J, Hanisch F-G, Neumann U (1991) Glycoconjugate J 8: 414–23.
Ueno K, Ando S, Yu RK (1978) J Lipid Res 19: 863–71.
Saito T, Hakomori S-I (1971) J Lipid Res 12: 257–59.
Müthing J, Neumann U (1993) Biomed Chromatogr 7: 158–61.
Müthing J, Unland F, Heitmann D, Orlich M, Hanisch F-G, Peter-Katalinić J, Knäuper V, Tschesche H, Kelm S, Schauer R, Lehmann J (1993) Glycoconjugate J 10: 120–26.
Müthing J, Peter-Katalinić J, Hanisch F-G, Unland F, Lehmann J (1994) Glycoconjugate J 11: 153–62.
Skipski VP (1975) Methods Enzymol 35: 396–425.
Svennerholm L (1957) Biochim Biophys Acta 24: 604–11.
Kasai M, Iwamori M, Nagai Y, Okumura K, Tada T (1980) Eur J Immunol 10: 175–80.
Bethke U, Kniep B, Mühlradt PF (1987) J Immunol 138: 4329–35.
Young WW Jr, MacDonald EMS, Nowinski RC, Hakomori S-I (1979) J Exp Med 150: 1008–19.
Bethke U, Müthing J, Schauder B, Conradt P, Mu¬hlradt PF (1986) J Immunol Methods 89: 111–16.
Müthing J, Mühlradt PF (1988) Anal Biochem 173: 10–17.
Müthing J, Steuer H, Peter-Katalinić J, Marx U, Bethke U, Neumann U, Lehmann J (1994) J Biochem 116: 64–73.
Dippold WG, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ (1980) Proc Natl Acad Sci USA 77: 6114–18.
Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Y, Koprowski H, Ginsburg V (1982) J Biol Chem 257: 14365–69.
Magnani JL, Smith DF, Ginsburg V (1980) Anal Biochem 109: 399–402.
Müthing J, Pörtner A, Jäger V (1992) Glycoconjugate J 9: 265–73.
Wu G, Ledeen RW (1988) Anal Biochem 173: 368–75.
Itonori S, Hidari K, Sanai Y, Taniguchi M, Nagai Y (1989) Glycoconjugate J 6: 551–60.
Puro K, Maury P, Huttunen K (1969) Biochim Biophys Acta 187: 230–35.
Iwamori M, Nagai Y (1981) J Biochem 89: 1253–64.
Iwamori M, Nagai Y (1978) J Biochem 84: 1609–15.
Nakamura K, Nagashima M, Sekine M, Igarashi M, Ariga T, Atsumi T, Miyatake T, Suzuki A, Yamakawa T (1983) Biochim Biophys Acta 752: 291–300.
Nakamura K, Hashimoto Y, Yamakawa T, Suzuki A (1988) J Biochem 103: 201–8.
Leskawa CL, Short CS (1988) Glycoconjugate J 5: 302.
Chien J-L, Hogan EL (1980) Biochim Biophys Acta 620: 454–61.
Ariga T, Sekine M, Nakamura K, Igarashi M, Nagashima M, Miyatake T, Suzuki M, Yamakawa T (1983) J Biochem 93: 889–93.
Chien J-L, Hogan EL (1983) J Biol Chem 258: 10727–30.
Dasgupta S, Chien J-L, Hogan EL, van Halbeek H (1991) J Lipid Res 32: 499–506.
Leskawa K C, Buse PE, Hogan EL, Garvin JL (1984) Neuro-chem Pathol 2: 19–29.
Li YT, Månsson JE, Vanier M-T, Svennerholm L (1973) J Biol Chem 248: 2634–36.
Ogawa K, Abe T, Yoshimura K, Nagashima K, Nagashima T (1985) Jpn J Exp Med 55: 123–27.
Chan K-FJ (1989) J Biol Chem 264: 18632–37.
Chan K-FJ, Liu Y (1991) Glycobiology 1: 193–203.
Hirabayashi Y, Koketsu K, Higashi H, Suzuki Y, Matsumoto M, Sugimoto M, Ogawa T (1986) Biochim Biophys Acta 876: 178–82.
Davidsson P, Fredman P, Svennerholm L (1989) J Chromatogr 496: 279–89.
Hamilton WB, Helling F, Lloyd KO, Livingston PO (1993) Int J Cancer 53: 566–73.
Partridge TA (1991) Muscle Nerve 14: 197–212.
Law PK, Bertorini TE, Goodwin TG, Chen M, Fang Q, Li H-J, Kirby DS, Florendo JA, Herrod H, Golden GS (1990) Lancet 336: 114–15.
Huard J, Bouchard JP, Roy R, Malouin F, Dansereau G, Labrecque C, Albert N, Richards CL, Lemieux B, Tremblay JP (1992) Muscle Nerve 15: 550–60.
Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM (1989) Nature 337: 176–79.
Barr E, Leiden JM (1991) Science 254: 1507–9.
Dhawan J, Pan LC, Pavlath GK, Travis MA, Lanctot AM, Blau HM (1991) Science 254: 1509–12.
Yao S-N, Kurachi K (1992) Proc Natl Acad Sci ºSA 89: 3357–61.
Jiao S, Gurevich V, Wolff JA (1993) Nature 362: 450–53.
Leskawa KC, Erwin RE, Buse PE, Hogan EL (1988) Mol Cell Biochem 83: 47–54.
Leskawa KC, Hogan EL (1990) Mol Cell Biochem 96: 163–73.
Cambron LD, Leskawa KC (1994) Mol Cell Biochem 130: 173–85.
Čačić M, Šoštarić K, Weber-Schu¬rholz S, Mu¬thing J (1995) Glycoconjugate J 12: 721–28.
McCurry KR, Kooyman DL, Alvarado CG, Cotterell AH, Martin MJ, Logan JS, Platt JL (1995) Nature Medicine 1: 423–27.
Reuter G, Schauer R (1988) Glycoconjugate J 5: 133–35.
IUPAC-IUB Commission on biochemical nomenclature (1977) Eur J Biochem 79: 11–21.
Svennerholm L (1963) J Neurochem 10: 613–23.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Muthing, J., Cacic, M. Glycosphingolipid expression in human skeletal and heart muscle assessed by immunostaining thin-layer chromatography. Glycoconj J 14, 19–28 (1997). https://doi.org/10.1023/A:1018552729572
Issue Date:
DOI: https://doi.org/10.1023/A:1018552729572